Pharmaceutical

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

AstraZeneca has announced the conclusion of its acquisition of Gracell Biotechnologies for approximately $1.2bn.

Feb 24, 2024 - 18:00
AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn
AstraZeneca has announced the conclusion of its acquisition of Gracell Biotechnologies for approximately $1.2bn.
Read the original article

Tags:

Previous Article

NICE recommends Pfizer’s Ritlecitinib for alopecia areata treatment

Next Article

AbbVie and Tentarix enter biologic development deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How using AI in clinical trials accelerates drug development

How using AI in clinical trials accelerates drug develo...

Jun 15, 2023

Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture

Listen: Biotech’s monkey shortage, the broken generics ...

Mar 30, 2023

FDA awarded record number of review designations to CRISPR drugs in 2023

FDA awarded record number of review designations to CRI...

Jan 31, 2024